PicoCELA (NASDAQ:PCLA) Shares Down 6.5% – Here’s What Happened

PicoCELA Inc. (NASDAQ:PCLA)’s share price was down 6.5% on Monday . The stock traded as low as $4.60 and last traded at $4.60. Approximately 10,022 shares changed hands during mid-day trading, a decline of 73% from the average daily volume of 37,098 shares. The stock had previously closed at $4.92.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PicoCELA in a research note on Friday, January 9th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

PicoCELA Price Performance

The business’s fifty day moving average price is $6.54 and its 200 day moving average price is $10.21. The company has a quick ratio of 1.57, a current ratio of 2.13 and a debt-to-equity ratio of 0.02.

Institutional Trading of PicoCELA

A hedge fund recently bought a new stake in PicoCELA stock. Jane Street Group LLC bought a new stake in PicoCELA Inc. (NASDAQ:PCLA) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 172,132 shares of the company’s stock, valued at approximately $52,000. Jane Street Group LLC owned about 18.92% of PicoCELA at the end of the most recent quarter.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.